FIELD: medicine.
SUBSTANCE: inventions group relates to medicine. Disclosed is the use of the non-steroidal anti-inflammatory drug floktafenin as an inhibitor of the main protease of SARS-CoV-2 for the treatment of coronavirus infection caused by SARS-CoV-2. Also disclosed is a method for treating SARS-CoV-2 coronavirus infection in a subject, including a human in need of such treatment, by inhibiting the SARS-CoV-2 major protease, comprising administering to the subject an effective amount of floctafenine.
EFFECT: inventions group provides not only a reduction in the symptoms of SARS-CoV-2 infection, but also a reduction in the symptoms of inflammation.
2 cl, 3 dwg
| Title | Year | Author | Number |
|---|---|---|---|
| METHODS OF TREATING CORONAVIRUS INFECTIONS | 2021 |
|
RU2825648C1 |
| METHODS FOR TREATING INFECTIOUS DISEASES CAUSED BY CORONAVIRUS | 2021 |
|
RU2772701C1 |
| APPLICATION OF A DERIVATIVE OF 1,3,5-TRIAZINE-2,4-DIAMINE FOR INHIBITING THE REPLICATION OF BETACORONAVIRUSES, INCLUDING SARS-COV-2 | 2021 |
|
RU2780249C1 |
| USING DALARGIN FOR PRODUCING AGENTS FOR TREATING COVID-19 CORONAVIRUS INFECTION | 2020 |
|
RU2728939C1 |
| THERAPEUTIC AGENT AGAINST CORONAVIRUS INCLUDING AN ELAEOCARPUS SYLVESTRIS EXTRACT | 2021 |
|
RU2780346C1 |
| PHILLYRIN AND ITS DERIVATIVES FOR SUPPRESSION OF THE 3CLPRO PROTEIN AND FIGHTING THE COVID-19 VIRUS | 2021 |
|
RU2804307C1 |
| AGENT FOR REDUCING RISK AND RELIEVING SYMPTOMS OF BETA-CORONAVIRUS INFECTION | 2021 |
|
RU2747890C1 |
| METHOD OF TREATING COVID-19 USING OX40 (CD134) RECEPTOR AGONISTS | 2020 |
|
RU2826983C2 |
| NEW APPLICATION OF NATURAL DOUBLE-STRANDED RNAS FOR THE TREATMENT AND/OR PREVENTION OF VIRAL INFECTIONS | 2022 |
|
RU2781903C1 |
| METHOD FOR PREVENTION OR TREATMENT OF CORONAVIRUS AND OTHER ACUTE RESPIRATORY VIRAL INFECTIONS | 2022 |
|
RU2794315C1 |
